Expert consensus on safety management of bone-modifying agents / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 622-628, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-887466
ABSTRACT
Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osteoporosis
/
Quality of Life
/
Safety Management
/
Consensus
/
Diphosphonates
/
Bone Density Conservation Agents
Type of study:
Practice guideline
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS